Clinical Trials Logo

Clinical Trial Summary

According to the peripheral trigger theory of migraine headaches, nociceptive inputs from irritated or compressed cranial nerve branches can lead to neurovascular changes in the brain that cause migraine headaches. Advanced treatments aimed at deactivating the peripheral trigger points can be administered to patients who have failed medical management of migraines. Those accepted advanced treatments include botulinum toxin A injection in order to temporarily paralyze muscles causing nerve compression, and surgery to release those compression points permanently. An advantage of surgery is the ability to release non-muscular causes of nerve compression, such as fascial bands or intersecting arteries. Botulinum toxin A injection into trigger sites has been shown in multiple studies to be effective at reducing the frequency and severity of migraine headaches, and is a very commonly administered treatment for refractory migraines. It is approved by the FDA for the treatment of chronic migraines. Similarly, surgical decompression of trigger sites has previously been shown to have superior clinical outcomes to medical management, through a randomized, blinded controlled-trial performed at Case Western Reserve in 2009. Patients either received actual decompression of the trigger sites, or sham surgery (exposure and visualization of the trigger sites, without decompression). At one-year follow-up, the group who underwent actual surgery demonstrated a statistically higher proportion with significant improvement in their migraines (83.7% vs. 57.7%, p=0.014), and with complete elimination of their migraines (57.1% vs. 3.8%, p<0.001). Several other reports have confirmed the good clinical outcomes of surgery demonstrated in this trial, and surgical decompression is now commonly performed by several surgeons around the United States. Prognostic factors predicting the success of surgical decompression in migraine headache treatment include older age of migraine onset, visual symptoms/aura, and 4-site decompression. Factors predicting failure of surgery include excessive operative blood loss, and surgery on only one or two trigger sites. One criticism of the studies on peripheral trigger decompression surgery for migraines has been that most of the results have originated from the same institution (Case Western Reserve), and from the same author (Guyuron). While several studies at other institutions have demonstrated positive outcomes of peripheral trigger decompression, these have only included a small number of patients. In addition, the sham surgery randomized-controlled trial has been criticized for not clarifying any prior treatments that patients had undergone before peripheral trigger deactivation, and for not showing how medication use patterns changed after surgery. Another criticism of that study was the fact that patients were examined by neurologists before the study but not after the study, and that surgery was performed on some patients with episodic migraines, who are known to not benefit from botulinum toxin. It is unclear what migraine types are most likely to benefit from surgical decompression. The investigators' goal is to perform a multi-center, prospective trial to demonstrate the effectiveness of peripheral trigger decompression in the treatment of migraine headaches, which would address the criticisms mentioned above. The main aim is to demonstrate that the positive results demonstrated by Guyuron et al are reproducible at other institutions and by other surgeons using similar techniques on different patient populations.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02351544
Study type Interventional
Source Ohio State University
Contact
Status Completed
Phase N/A
Start date September 2015
Completion date June 2022

See also
  Status Clinical Trial Phase
Completed NCT06342232 - The Efficacy of Neurofeedback Mindfulness in Migraine Management N/A
Completed NCT00665236 - Craniosacral Therapy in Migraine: A Feasibility Study N/A
Completed NCT01706003 - The Utility of Telemedicine in the Management of Migraine
Terminated NCT01944059 - Theramine® in the Prevention of Migraine Headache Phase 4
Terminated NCT01629329 - Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine Phase 4
Completed NCT00792636 - A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Phase 4
Not yet recruiting NCT05536635 - Effect of Breathing Techniques on Migraine Attacks and Severity N/A
Completed NCT00442221 - The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months Phase 3
Completed NCT02057315 - Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine Phase 1/Phase 2
Completed NCT00109083 - A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine Phase 2
Completed NCT02098499 - Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial Phase 4
Completed NCT00714727 - Set Point Acupuncture for Migraines Using a Digital Assistant Phase 1
Completed NCT00434083 - To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches Phase 3
Completed NCT00960245 - Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions Phase 1
Completed NCT02856802 - An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg) Phase 2
Completed NCT00355056 - PREMIUM Migraine Trial N/A
Completed NCT01118988 - Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents N/A
Completed NCT00433732 - To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches Phase 3
Completed NCT00750594 - Patent Foramen Ovale in Children With Migraine Headaches N/A